Lancet Respir Med:地缘经济差异对急性呼吸窘迫综合征患者的影响

2017-06-15 zhangfan MedSci原创

急性呼吸窘迫综合征患者的疾病程度、医生处理方法以及病人结果存在严重的地缘经济差异

目前有关急性呼吸窘迫综合征(ARDS)患者的人口地缘经济变化对患者的治疗和临床结果的研究资料很少。近日研究人员根据大型观察性严重急性呼吸衰竭研究(LUNG SAFE)资料研究了地缘经济变化对疾病的影响。

LUNG SAFE在2014年冬季展开,持续4周,对6大洲50个国家的459个ICU病房进行考察,患者有创或无创通气。试验的次要目标之一是对ARDS患者的人口统计学和治疗结果的变化进行研究。研究人员使用2016世界银行国家分类定义三个主要地缘经济集团,即欧洲高收入国家(Europe-High),世界其他地区的高收入国家(rWORLD-High)和中等收入国家(Middle),比较上述3个地区患者结果差异。

有2813名符合标准的ARDS参与者,其中1521人(54%)来自Europe-High国家,746人(27%)来自rWORLD-High地区,546人(19%)来自Middle国家。研究发现,人口统计学的地理变化导致ARDS风险因素和并发症存在显著差异。在rWORLD-High地区,严重ARDS患者或动脉氧分压(PaO2)对吸入气氧浓度(FiO2)分数小于150患者的比例显著低于其他二组,Europe-High国家俯卧位和神经肌肉阻滞的使用率高于其他地区,rWORLD-High国家患者有创机械通气的调整时间和住院时间明显缩短,高国民人均收入可增加ARDS相关医院生存率。

研究发现急性呼吸窘迫综合征患者的疾病程度、医生处理方法以及病人结果存在严重的地缘经济差异。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1829018, encodeId=38d618290182b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Aug 17 00:02:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430849, encodeId=3046143084941, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jun 17 02:02:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582227, encodeId=6a93158222e14, content=<a href='/topic/show?id=e46f396832b' target=_blank style='color:#2F92EE;'>#呼吸窘迫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39683, encryptionId=e46f396832b, topicName=呼吸窘迫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22be16898890, createdName=12498cf9m40(暂无昵称), createdTime=Sat Jun 17 02:02:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607651, encodeId=7163160e6519f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Jun 17 02:02:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2017-08-17 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1829018, encodeId=38d618290182b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Aug 17 00:02:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430849, encodeId=3046143084941, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jun 17 02:02:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582227, encodeId=6a93158222e14, content=<a href='/topic/show?id=e46f396832b' target=_blank style='color:#2F92EE;'>#呼吸窘迫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39683, encryptionId=e46f396832b, topicName=呼吸窘迫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22be16898890, createdName=12498cf9m40(暂无昵称), createdTime=Sat Jun 17 02:02:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607651, encodeId=7163160e6519f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Jun 17 02:02:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2017-06-17 zhouqu_8
  3. [GetPortalCommentsPageByObjectIdResponse(id=1829018, encodeId=38d618290182b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Aug 17 00:02:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430849, encodeId=3046143084941, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jun 17 02:02:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582227, encodeId=6a93158222e14, content=<a href='/topic/show?id=e46f396832b' target=_blank style='color:#2F92EE;'>#呼吸窘迫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39683, encryptionId=e46f396832b, topicName=呼吸窘迫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22be16898890, createdName=12498cf9m40(暂无昵称), createdTime=Sat Jun 17 02:02:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607651, encodeId=7163160e6519f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Jun 17 02:02:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1829018, encodeId=38d618290182b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Aug 17 00:02:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430849, encodeId=3046143084941, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jun 17 02:02:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582227, encodeId=6a93158222e14, content=<a href='/topic/show?id=e46f396832b' target=_blank style='color:#2F92EE;'>#呼吸窘迫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39683, encryptionId=e46f396832b, topicName=呼吸窘迫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22be16898890, createdName=12498cf9m40(暂无昵称), createdTime=Sat Jun 17 02:02:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607651, encodeId=7163160e6519f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Jun 17 02:02:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2017-06-17 柳叶一刀

相关资讯

超声在急性呼吸窘迫综合征合并急性肺源性心脏病诊断和治疗中的应用

作者:袁婷 姚尚龙 尚游 华中科技大学同济医学院附属协和医院ICU 急性呼吸窘迫综合征(ARDS)的常见并发症除感染、休克、多器官功能障碍综合征(MODS)外,还包括急性肺源性心脏病(ACP)和右心功能衰竭(右心衰竭)。Phua等在系统性回顾研究中指出,近年来ARDS的病死率并无明显降低。Legras等的研究表明,ARDS患者28 d病死率达23%,合并

Crit Care Med:中重度急性呼吸窘迫综合征患者进行低温治疗是否可行?

有研究表明,低温可能对急性呼吸窘迫综合征有益,但低温可能会引起发抖从而增加新陈代谢。近期,一项发表在杂志Crit Care Med上的研究旨在评估接受神经肌肉阻滞治疗(患者无法颤抖)的急性呼吸窘迫综合征患者中进行低体温的可行性。此项研究为回顾性、前瞻性开放标签的可行性研究。根据柏林标准对58例急性呼吸窘迫综合征患者进行回顾,PaO2 / FIO2小于150的患者接受神经肌肉阻滞治疗。八名PaO2

Lancet Respir Med:角质细胞生长因子不能改善急性呼吸窘迫综合征

角质细胞生长因子不能改善急性呼吸窘迫综合征患者生理或临床结果反而对患者健康有害

Ann Surg:线粒体产物诱导急性呼吸窘迫综合征

我们的目的是,利用注入线粒体损伤相关分子产物,建立一个可重复的肺损伤模型。我们的目标是,损伤相关分子模式介导的器官损伤的病理生理反应特征。我们对急性呼吸窘迫综合征的理解仍然有显着的差距,部分原因是由于缺乏这种疾病相关的临床适用的动物模型。通过非感染的动物模型,需要明白组织损伤致肺损伤的信号,以及对这种损伤的反应。10头猪(35-45公斤)静脉注射破坏线粒体的产品,然后长达6小时的一般麻醉。将这些动

2016小儿急性呼吸窘迫综合征诊疗技术规范发布

本文介绍一家三级儿童医院重症医学科的小儿急性呼吸窘迫综合征的技术诊疗规范,包括其病因判断、诊断标准、诊断时注意事项、诊断流程图、辅助检查及治疗等。在治疗中强调了病因治疗、保守补液、肺保护性通气策略、俯卧位通气及镇痛镇静肌松等全文获取:下载地址:指南下载(需要扣积分2分, 梅斯医学APP免积分下载) 

Thorax:阿司匹林可降低LPS诱导的急性呼吸窘迫综合征人体模型的肺部炎症

这是第一个前瞻性人体研究,其数据表明无论是低剂量还是高剂量阿司匹林都能够抑制肺中性粒细胞性炎症。进一步的临床研究可以评估阿司匹林在急性呼吸窘迫综合征的预防和治疗中的作用。